Effect of PON1 Gene Polymorphisms in Turkish Patients with Hepatocellular Carcinoma

Overview

Journal Meta Gene

Publisher Elsevier

Specialty Genetics

Date 2015 Jan 22

PMID 25606379

Citations 7

Authors

Hikmet Akkiz

Sedef Kuran

Ersin Akgollu

Oguz Uskudar

Aynur Bekar

Suleyman Bayram

Selcuk Yildirim

Yakup Ulger

Berrin Yalinbas Kaya

Mahmut Sansal

Ercan Cinar

Affiliations

Soon will be listed here.

Abstract

Background: Reactive oxygen species (ROS) can oxidize biological molecules that mediate carcinogenesis by causing metabolic malfunction and damage to DNA. Human serum paraoxonases (PON1, PON2 and PON3) play a role in antioxidant defense and protect the cell against ROS. PON1 polymorphisms Q192R and L55M have been shown to be associated with several human cancers, but their association with hepatocellular carcinoma (HCC) has yet to be investigated.

Methods: We performed genotyping analysis using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a hospital-based case-control study of 217 confirmed HCC patients and 217 age-, gender-, smoking- and alcohol consumption-matched cancer-free controls in Turkish population.

Results: Q192R and L55M polymorphisms were in significant linkage disequilibrium (LD) (D' = 0.77). However, allele, genotype and haplotype analysis showed no significant differences between the risks of HCC and PON1 polymorphisms. Moreover, no significant differences were found between clinical findings, clinicopathological features and sex in comparison with the PON1 genotypes in HCC group.

Conclusion: Our results suggest for the first time that neither the Q192R polymorphism nor the L55M polymorphism has relationship with the risk of developing HCC. Further independent studies are required to clarify the possible role of PON1 gene Q192R and L55M polymorphisms on the risk of developing HCC in a larger series and also in patients of different ethnic origins.

Citing Articles

The association of the paraoxonase 1 Q192R polymorphism with coronary artery disease (CAD) and cardiometabolic risk factors in Iranian patients suspected of CAD.

Darand M, Salehi-Abargouei A, Vahidi Mehrjardi M, Feizi A, Seyedhossaini S, Askari G Front Cardiovasc Med. 2023; 9:1037940.

PMID: 36741829 PMC: 9890597. DOI: 10.3389/fcvm.2022.1037940.

Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma.

Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J Cancer Cell Int. 2021; 21(1):621.

PMID: 34819088 PMC: 8613962. DOI: 10.1186/s12935-021-02326-8.

The Association between PON1 (Q192R and L55M) Gene Polymorphisms and Risk of Cancer: A Meta-Analysis Based on 43 Studies.

Pan X, Huang L, Li M, Mo D, Liang Y, Liu Z Biomed Res Int. 2019; 2019:5897505.

PMID: 31467900 PMC: 6699405. DOI: 10.1155/2019/5897505.

Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival.

Yu Z, Ou Q, Chen F, Bi J, Li W, Ma J J Transl Med. 2018; 16(1):327.

PMID: 30477582 PMC: 6258254. DOI: 10.1186/s12967-018-1707-0.

Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma.

Cai J, Yuan S, Yang F, Tao Q, Yang Y, Xu Q Oncotarget. 2016; 7(43):70045-70057.

PMID: 27661119 PMC: 5342533. DOI: 10.18632/oncotarget.12145.

References

Mogarekar M, Talekar S . Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B. Indian J Gastroenterol. 2013; 32(5):307-10. DOI: 10.1007/s12664-013-0334-1. View

Rajkovic M, Barisic K, Juretic D, Zanic Grubisic T, Flegar-Mestric Z, Rumora L . Polymorphisms of pon1 and pon2 genes in hemodialyzed patients. Clin Biochem. 2011; 44(12):964-8. DOI: 10.1016/j.clinbiochem.2011.05.012. View

Riedmaier S, Klein K, Winter S, Hofmann U, Schwab M, Zanger U . Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Front Pharmacol. 2011; 2:41. PMC: 3147178. DOI: 10.3389/fphar.2011.00041. View

Cejas P, Casado E, Belda-Iniesta C, de Castro J, Espinosa E, Redondo A . Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control. 2004; 15(7):707-19. DOI: 10.1023/B:CACO.0000036189.61607.52. View

Stevens V, Rodriguez C, Pavluck A, Thun M, Calle E . Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2006; 15(6):1226-8. DOI: 10.1158/1055-9965.EPI-05-0930. View

Keskin M, Dolar E, Dirican M, Kiyici M, Yilmaz Y, Gurel S . Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity. Intern Med J. 2009; 39(4):243-8. DOI: 10.1111/j.1445-5994.2009.01793.x. View

Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L . Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48(2):261-8. View

van der Logt E, Janssen C, Van Hooijdonk Z, Roelofs H, Wobbes T, Nagengast F . No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res. 2005; 25(2B):1465-70. View

Ludwig J, Weinstein J . Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5(11):845-56. DOI: 10.1038/nrc1739. View

10.

Kim Y, Lee H . Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005; 48(1):10-5. DOI: 10.1159/000082089. View

11.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

12.

Macharia M, Hassan M, Blackhurst D, Erasmus R, Matsha T . The growing importance of PON1 in cardiovascular health: a review. J Cardiovasc Med (Hagerstown). 2012; 13(7):443-53. DOI: 10.2459/JCM.0b013e328354e3ac. View

13.

Wang H, Li L, Ding L, Zhang Z, Pu C . Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese Han population. J Investig Med. 2012; 60(3):592-7. DOI: 10.2310/JIM.0b013e318245d557. View

14.

Mackness B, Mackness M, Arrol S, Turkie W, Durrington P . Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997; 122(2):265-8. PMC: 1564940. DOI: 10.1038/sj.bjp.0701390. View

15.

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

16.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

17.

De Roos A, Gold L, Wang S, Hartge P, Cerhan J, Cozen W . Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1647-53. DOI: 10.1158/1055-9965.EPI-06-0193. View

18.

Gold L, De Roos A, Brown E, Lan Q, Milliken K, Davis S . Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol. 2009; 33(3-4):276-80. PMC: 2808169. DOI: 10.1016/j.canep.2009.08.005. View

19.

Kato N, Ji G, Wang Y, Baba M, Hoshida Y, Otsuka M . Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005; 42(4):846-53. DOI: 10.1002/hep.20860. View

20.

Lurie G, Wilkens L, Thompson P, McDuffie K, Carney M, Terada K . Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2070-7. PMC: 2729507. DOI: 10.1158/1055-9965.EPI-08-0145. View